Shao Mingli attended the 3rd meeting of the 9th Pharmacopoeia Committee

On February 1, 2010, the third committee meeting of the ninth Pharmacopoeia Committee and the summary meeting of the preparation of 2010 edition of Chinese Pharmacopoeia were held in Beijing Shao Mingli, Vice Minister of the Ministry of health, director of the State Food and Drug Administration and chairman of the ninth Pharmacopoeia Committee, attended the meeting and delivered an important speech Wu Zhen, deputy director of the State Food and Drug Administration and Secretary General of the Pharmacopoeia Committee, presided over the meeting and read out the decision on Commending 21 Pharmacopoeia members including Xiao Peigen Bian Zhenjia, deputy director general of the State Food and drug administration, Yu Wenming, deputy director general of the State Administration of traditional Chinese medicine, and relevant responsible comrades from ministries and commissions such as the Ministry of health, the National Ethnic Affairs Commission, the Ministry of science and technology, and the Ministry of health of the general post of the people's Liberation Army attended the meeting Shao Mingli fully affirmed the achievements made in the preparation of 2010 edition of Chinese Pharmacopoeia under the close cooperation, careful arrangement and efforts of the ninth Pharmacopoeia Committee and its permanent organization, the general Pharmacopoeia members and the drafting and review units of drug standards, and further explained the important position of the current drug standard work, as well as the historical opportunities and challenges faced It is hoped that all drug standard workers will take 2010 edition of Chinese Pharmacopoeia as a new starting point of drug standard work, seriously consider the development direction of national drug standard work under the new situation, further do a good job in the preparation and revision of Chinese Pharmacopoeia and national drug standard, and realize the new development of national drug standard work: first, establish and improve the drug standard legal system Carefully sort out the provisions of laws and regulations in the drug administration law and the regulations for the implementation of the drug administration law, deeply analyze the problems existing in the work of national drug standards, deeply consider the functional orientation and development direction of the national pharmacopoeia committee, sort out the mechanism of drug standards work from the source, clarify the responsibilities of relevant organizations in the work of drug standards, and institutionalize the work of drug standards Standardization provides legal guarantee Second, we should constantly improve the overall level of national drug standards We should seize the opportunity to implement the national essential drug system and accelerate the implementation of the national action plan for improving drug standards In the near future, we should focus on the improvement of drug standards for high-risk varieties such as national essential drug catalogue, injections, vaccines, and several kinds of products such as traditional Chinese medicine and ethnic medicine Third, we should continue to optimize the management mechanism of drug standards This paper comprehensively summarizes the experience of the preparation of the Chinese pharmacopoeia in the previous stage, analyzes the shortcomings in the management of drug standards, constantly optimizes and improves the management mechanism of drug standards, practically strengthens the certification and assessment of the qualifications of institutions undertaking the scientific research tasks of the Chinese Pharmacopoeia, and establishes an effective scientific management system Fourth, we should actively plan the preparation of the 2015 edition of the Chinese Pharmacopoeia The improvement of drug standards is a continuous and endless development process We should put the preparation of 2015 edition of Chinese Pharmacopoeia on the work schedule, make scientific arrangements and actively promote it It is necessary to work out the working outline of 2015 edition of Chinese Pharmacopoeia, prepare the scientific research plan and arrange the basic research in advance Fifth, we should speed up the construction of a high-quality and compound talent team It is necessary to strengthen the team building of Pharmacopoeia Committee members, establish incentive mechanism, support them in-depth basic research, actively participate in international standardization activities, and constantly innovate the quality control research of traditional Chinese medicine; it is necessary to strengthen the training of young experts, take the way of going out and inviting in, and cultivate a group of young backbone forces who are proficient in business, familiar with laws and regulations, and have strong international communication ability We should be concerned about the team building of the permanent establishment of the Pharmacopoeia Committee, build a better platform for the development of this team, provide more support, and encourage everyone to become and make the best of their talents The 2010 edition of Chinese pharmacopoeia is the ninth edition of Pharmacopoeia since the founding of the people's Republic of China This edition of Pharmacopoeia has a total of 4567 varieties, including 1386 new varieties; Pharmacopoeia I has a total of 2165 new varieties, including 1019 new ones and 634 revised ones; Pharmacopoeia II has a total of chemical drugs, antibiotics, biochemical drugs and radioactive drugs There are 2271 products and pharmaceutical accessories in total, including 330 new ones and 1500 revised ones; 131 varieties of biological products are collected in the third part of Pharmacopoeia, including 37 new ones and 94 revised ones; 47 new ones and 154 revised ones in the appendix of Pharmacopoeia The successful completion of the preparation of 2010 edition of Chinese Pharmacopoeia marks that the national action plan for improving drug standards has achieved important stage results, which is of great significance to ensure public drug safety and promote the healthy development of China's medical and health undertakings.